MedTrace Logo

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

NCT06616532 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2026-05-22

No results posted yet for this study

Summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC

Conditions

Interventions

DRUG

PM8002

Following a predefined dose and date.

DRUG

Paclitaxel

175mg/m2 via IV infusion on Day 1 Q3W

DRUG

Topotecan

1.25mg/m2/day via IV infusion on Days 1-5 Q3W

Sponsors & Collaborators

  • Biotheus Inc.

    lead INDUSTRY

Principal Investigators

  • Caicun Zhou · Shanghai East Hospital

  • Haifeng Liu · Jilin Provincial Tumor Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2027-01-25
Completion
2028-12-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06616532 on ClinicalTrials.gov